The Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) Amyloid Removal Trial (ART): A Phase IIIb/IV Open-Label Study of Lecanemab to Evaluate Prevention and Progression of Dominantly Inherited Alzheimer's Disease
Latest Information Update: 08 Apr 2025
At a glance
- Drugs Lecanemab (Primary) ; Gantenerumab
- Indications Alzheimer's disease
- Focus Therapeutic Use
- Acronyms DIAN-TU
Most Recent Events
- 03 Apr 2025 Planned End Date changed from 1 Nov 2029 to 1 Jun 2030.
- 03 Apr 2025 Planned primary completion date changed from 1 Nov 2029 to 1 Jun 2030.
- 03 Jul 2024 Status changed from not yet recruiting to recruiting.